Trial Profile
A clinical study to evaluate the biological effects of pre-operative intravenous administration of JX-594 (thymidine kinase-deactivated Vaccinia virus plus GM-CSF) prior to planned surgical resection of locally advanced/poor prognosis or metastatic cancers
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Feb 2020
Price :
$35
*
At a glance
- Drugs Granulocyte macrophage colony stimulating factor (Primary) ; Pexastimogene devacirepvec (Primary)
- Indications Bladder cancer; Colorectal cancer; Liver cancer; Malignant melanoma; Renal cell carcinoma
- Focus Pharmacokinetics
- Acronyms Pre-Operative-JX594
- 03 Apr 2019 Status changed from active, no longer recruiting to completed.
- 19 Sep 2018 According to a Transgene media release, the final data from this trial will be published in an upcoming paper and will be presented at a future scientific conference.
- 05 Jun 2018 Results (n=8) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.